Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 937.20, up by 1.55 points or 0.17% from its previous closing of Rs. 935.65 on the BSE.

The scrip opened at Rs. 930.00 and has touched a high and low of Rs. 939.15 and Rs. 908.25 respectively. So far 224764 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 748.15 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 965.15 and Rs. 885.00 respectively. The current market cap of the company is Rs. 225476.66 crore.

The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 31.51% and 13.78% respectively.

Sun Pharmaceutical Industries has received US Food and Drug Administration (USFDA) approval for its Supplemental New Drug Application (sNDA) for XiminoTM (Minocycline HCl) extended-release capsules 45 mg, 90 mg and 135 mg.

Ximino extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. This approval further strengthens the company’s branded dermatology portfolio in the US. It expects Ximino extended-release capsules to be available for patients during the fourth quarter of 2015.

Sun Pharmaceutical Industries is a leading Indian pharmaceutical company engaged in developing, manufacturing and marketing formulations and APIs. Its business is broadly categorized in four segments - India Branded Generics, US Formulations, International Generics or RoW business and APIs.